In clinical setting, MUC1 overexpression and genomic alterations were associated with significantly worse overall survival, cancer-specific survival, and recurrence-free survival confirming MUC1 as a survival-related prognostic factor in ccRCC. This evidence concerns the gene MUC1 and nonpapillary renal cell carcinoma.